ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GENSCI128

A development code. Also written as “GenSci128 tablets”.

Its studies are led by Changchun GeneScience Pharmaceutical.

Furthest: phase 1, since Mar 19, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical11 open or runningphase 1since Mar 19, 2025Mar 19, 2025Dec 2027phase 1 · NCT06908434

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2025First study: phase 1 study in Solid Tumors Harboring a TP53 Y220C MutationFirst studyNCT06908434 · 82 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in Solid Tumors Harboring a TP53 Y220C MutationNCT06908434

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06908434Solid Tumors Harboring a TP53 Y220C Mutation · China1RecruitingDec 202782

How it is read

Names in the registry

  • “GenSci128 tablets”, 1 entry

Codes read as this program: GENSCI128.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.